New Customizable Biophysics Services
New Customizable Biophysics Services
Release date: 3/9/2023
SAN DIEGO, CA – Eurofins Discovery announces valuable new developments to its custom Biophysics Services. Biophysical assays are now an integral part of the Early Discovery service line. They employ high-quality tailor-made targeted proteins developed by Eurofins DiscoverX®
SAN DIEGO, CA – March 9, 2023 — Eurofins Discovery, the leading provider of products and services to the drug discovery industry, announces valuable new developments to its custom Biophysics Services. Biophysical assays are now an integral part of the Early Discovery service line, and are executed in purpose-built laboratory space. Performed on fragments and small molecules as well as targeted protein degradation (PROTACs®), they employ high-quality tailor-made targeted proteins developed by Eurofins DiscoverX®, the trusted product solutions provider that is part of Eurofins Discovery.
In the early drug discovery process, biophysics has been proven to be crucial in identifying and characterizing small molecules for targets of interest. From hit identification to lead optimization, biophysics is specifically instrumental in finding chemical leads with well-described mechanisms of action. Available as stand-alone LeadHunter® services as well as a part of an integrated DiscoveryOne™ program, Eurofins Discovery uses state-of-the-art equipment to support clients at multiple stages of their drug discovery projects.
Eurofins Discovery’s Biophysics Services harnesses the power of different cutting-edge technologies. including SPR, MST (TRIC) & Spectral Shift, TSA, ITC and Mass Spectrometry. Drawing on its extensive scientific expertise, the team supports fragment-based screening campaigns using relevant fragment libraries, follow-up strategies for hit profiling, as well as Medicinal Chemistry analysis to support Activity Relationships (SAR) programs.
By using the different and complementary biophysics technologies available, clients can develop a full understanding of the affinity of the interaction, the kinetics, the thermodynamics parameters and the mechanism of action (MoA) of their small molecules — saving clients time and money down the road.
About Eurofins Discovery
Eurofins Discovery is recognized as the industry leader for providing drug discovery researchers with the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. In addition to in vitro safety pharmacology strengths, we also offer a broad portfolio of over 3,500 drug discovery services and 1,800 products. These include in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes. The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a single outsourcing provider (CRO) for all their drug discovery programs.
Eurofins – a global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is a global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing.
With over 61,000 staff across a network of more than 940 laboratories in over 59 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.